circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling

Jiang Zhu,Yuming Luo,Yue Zhao,Yao Kong,Hanhao Zheng,Yuting Li,Bowen Gao,Le Ai,Hao Huang,Jian Huang,Zhihua Li,Changhao Chen
DOI: https://doi.org/10.1016/j.ymthe.2021.01.031
IF: 12.91
2021-05-01
Molecular Therapy
Abstract:<p>Lymphatic metastasis constitutes a leading cause of recurrence and mortality in bladder cancer. Accumulating evidence indicates that lymphangiogenesis is indispensable to trigger lymphatic metastasis. However, the specific mechanism is poorly understood. In the present study, we revealed a pathway involved in lymphatic metastasis of bladder cancer, in which a circular RNA (circRNA) facilitated lymphangiogenesis in a vascular endothelial growth factor C (VEGF-C) independent manner. Novel circRNA circEHBP1 was markedly upregulated in bladder cancer and correlated positively with lymphatic metastasis and poor prognosis of patients with bladder cancer. CircEHBP1 upregulated transforming growth factor beta receptor 1 (<em>TGFBR1</em>) expression through physically binding to miR-130a-3p and antagonizing the suppression effect of miR-130a-3p on the 3' UTR region of <em>TGFBR1</em>. Subsequently, circEHBP1-mediated TGFβR1 overexpression activated the TGF-β/SMAD3 signaling pathway, thereby promoting the secretion of VEGF-D and driving lymphangiogenesis and lymphatic metastasis in bladder cancer. Importantly, administration of VEGF-D neutralizing antibodies remarkably blocked circEHBP1-induced lymphangiogenesis and lymphatic metastasis <em>in vivo</em>. Our findings highlighted that the circEHBP1/miR-130a-3p/TGFβR1/VEGF-D axis contributes to lymphangiogenesis and lymphatic metastasis of bladder cancer independent of VEGF-C, which might lead to the development of circEHBP1 as a potential biomarker and promising therapeutic target for lymphatic metastasis in bladder cancer.</p>
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the specific mechanisms of lymphangiogenesis and lymphatic metastasis in bladder cancer, especially exploring the role of a new circular RNA (circRNA), namely circEHBP1, in promoting these processes. The paper points out that although vascular endothelial growth factor C (VEGF - C) is known to play a key role in lymphangiogenesis, some bladder cancer patients with lymph node metastasis show the phenomenon of low VEGF - C expression, which suggests that there are VEGF - C - independent lymphangiogenesis mechanisms. Therefore, the researchers explored the mechanism by which circEHBP1 promotes lymphangiogenesis and lymphatic metastasis through the miR - 130a - 3p/TGFβR1/VEGF - D signaling pathway, and this finding may provide a new target for treating lymphatic metastasis of bladder cancer. Specifically, the paper reveals the following points: 1. **The up - regulation of circEHBP1 is related to lymphatic metastasis**: The study found that circEHBP1 was significantly up - regulated in bladder cancer tissues, and its expression level was positively correlated with lymphatic metastasis and poor prognosis of patients. 2. **circEHBP1 promotes lymphangiogenesis and lymphatic metastasis through the miR - 130a - 3p/TGFβR1/VEGF - D axis**: circEHBP1 activates the TGF - β/SMAD3 signaling pathway by binding to and inhibiting the inhibitory effect of miR - 130a - 3p on TGFβR1, further increasing the secretion of VEGF - D, and finally promoting lymphangiogenesis and lymphatic metastasis. 3. **VEGF - D neutralizing antibody can block circEHBP1 - induced lymphangiogenesis and lymphatic metastasis**: In vivo experiments, the use of VEGF - D neutralizing antibody can significantly inhibit circEHBP1 - induced lymphangiogenesis and lymphatic metastasis and prolong the survival time of mice. In summary, this paper aims to reveal the mechanism of circEHBP1 in VEGF - C - independent lymphangiogenesis and lymphatic metastasis, and provides new potential targets for the treatment of bladder cancer.